Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Non Small Cell Lung Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Lung Cancer (4035
)
Lung Adenocarcinoma (638
)
Lung Non-Squamous Non-Small Cell Cancer (147
)
Lung Non-Small Cell Squamous Cancer (111
)
Lung Cancer (4035
)
Lung Adenocarcinoma (638
)
Lung Non-Squamous Non-Small Cell Cancer (147
)
Lung Non-Small Cell Squamous Cancer (111
)
›
Associations
(3548)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
Anticancer Res - 4 days (New C3)
atezolizumab
Sensitive
:
A1
Anticancer Res - 4d
atezolizumab
Sensitive: A1 - Approval
Anticancer Res - 4 days
atezolizumab
Sensitive
:
A1
Anticancer Res - 4 days - (New C3)
BIRC5 overexpression
Non Small Cell Lung Cancer
BIRC5 overexpression
Non Small Cell Lung Cancer
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Asian Pac J Cancer Prev - 4 days (New C3)
carboplatin + paclitaxel
Sensitive
:
C3
Asian Pac J Cancer Prev - 4d
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Asian Pac J Cancer Prev - 4 days
carboplatin + paclitaxel
Sensitive
:
C3
Asian Pac J Cancer Prev - 4 days - (New C3)
RRM1 overexpression
Non Small Cell Lung Cancer
RRM1 overexpression
Non Small Cell Lung Cancer
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Asian Pac J Cancer Prev - 4 days (New C3)
carboplatin + paclitaxel
Sensitive
:
C3
Asian Pac J Cancer Prev - 4d
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Asian Pac J Cancer Prev - 4 days
carboplatin + paclitaxel
Sensitive
:
C3
Asian Pac J Cancer Prev - 4 days - (New C3)
TUBB3 underexpression
Non Small Cell Lung Cancer
TUBB3 underexpression
Non Small Cell Lung Cancer
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Asian Pac J Cancer Prev - 4 days (New C3)
carboplatin + paclitaxel
Sensitive
:
C3
Asian Pac J Cancer Prev - 4d
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Asian Pac J Cancer Prev - 4 days
carboplatin + paclitaxel
Sensitive
:
C3
Asian Pac J Cancer Prev - 4 days - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
amivantamab-vmjw + lazertinib
Sensitive: B - Late Trials
J&J Press Release - 5 days (New B)
amivantamab-vmjw + lazertinib
Sensitive
:
B
J&J Press Release - 5d
amivantamab-vmjw + lazertinib
Sensitive: B - Late Trials
J&J Press Release - 5 days
amivantamab-vmjw + lazertinib
Sensitive
:
B
J&J Press Release - 5 days - (New B)
ROS1 mutation
Non Small Cell Lung Cancer
ROS1 mutation
Non Small Cell Lung Cancer
crizotinib
Sensitive: C4 – Case Studies
J Med Case Rep - 5 days (New C4)
crizotinib
Sensitive
:
C4
J Med Case Rep - 5d
crizotinib
Sensitive: C4 – Case Studies
J Med Case Rep - 5 days
crizotinib
Sensitive
:
C4
J Med Case Rep - 5 days - (New C4)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: B - Late Trials
Front Oncol - 6 days (New C3)
aumolertinib
Sensitive
:
B
Front Oncol - 6d
aumolertinib
Sensitive: B - Late Trials
Front Oncol - 6 days
aumolertinib
Sensitive
:
B
Front Oncol - 6 days - (New C3)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 week (New B)
nivolumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1wk
nivolumab
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 week
nivolumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1 week - (New B)
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
MYTX-011
Sensitive: B - Late Trials
Businesswire - 1 week (New B)
MYTX-011
Sensitive
:
B
Businesswire - 1wk
MYTX-011
Sensitive: B - Late Trials
Businesswire - 1 week
MYTX-011
Sensitive
:
B
Businesswire - 1 week - (New B)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 1 week (New C3)
afatinib
Sensitive
:
A1
Thorac Cancer - 1wk
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 1 week
afatinib
Sensitive
:
A1
Thorac Cancer - 1 week - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 1 week (New C3)
afatinib
Sensitive
:
A1
Thorac Cancer - 1wk
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 1 week
afatinib
Sensitive
:
A1
Thorac Cancer - 1 week - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
erlotinib
Sensitive: A1 - Approval
Thorac Cancer - 1 week (New C3)
erlotinib
Sensitive
:
A1
Thorac Cancer - 1wk
erlotinib
Sensitive: A1 - Approval
Thorac Cancer - 1 week
erlotinib
Sensitive
:
A1
Thorac Cancer - 1 week - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
icotinib
Sensitive: B - Late Trials
Authorea - 1 week (New C3)
icotinib
Sensitive
:
B
Authorea - 1wk
icotinib
Sensitive: B - Late Trials
Authorea - 1 week
icotinib
Sensitive
:
B
Authorea - 1 week - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
Thorac Cancer - 1 week (New C3)
pyrotinib
Sensitive
:
C2
Thorac Cancer - 1wk
pyrotinib
Sensitive: C2 – Inclusion Criteria
Thorac Cancer - 1 week
pyrotinib
Sensitive
:
C2
Thorac Cancer - 1 week - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
c-MET inhibitor
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week (New C3)
c-MET inhibitor
Sensitive
:
C3
JTO Clin Res Rep - 1wk
c-MET inhibitor
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week
c-MET inhibitor
Sensitive
:
C3
JTO Clin Res Rep - 1 week - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
AZD3759
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week (New C3)
AZD3759
Sensitive
:
C3
EClinicalMedicine - 1wk
AZD3759
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week
AZD3759
Sensitive
:
C3
EClinicalMedicine - 1 week - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
AZD3759
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week (New C3)
AZD3759
Sensitive
:
C3
EClinicalMedicine - 1wk
AZD3759
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week
AZD3759
Sensitive
:
C3
EClinicalMedicine - 1 week - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week (New C3)
PD1 inhibitor
Sensitive
:
C3
JTO Clin Res Rep - 1wk
PD1 inhibitor
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week
PD1 inhibitor
Sensitive
:
C3
JTO Clin Res Rep - 1 week - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
aglatimagene besadenovec
Sensitive: C3 – Early Trials
BioSpace - 1 week (New C3)
aglatimagene besadenovec
Sensitive
:
C3
BioSpace - 1wk
aglatimagene besadenovec
Sensitive: C3 – Early Trials
BioSpace - 1 week
aglatimagene besadenovec
Sensitive
:
C3
BioSpace - 1 week - (New C3)
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
aglatimagene besadenovec
Sensitive: C3 – Early Trials
BioSpace - 1 week (New C3)
aglatimagene besadenovec
Sensitive
:
C3
BioSpace - 1wk
aglatimagene besadenovec
Sensitive: C3 – Early Trials
BioSpace - 1 week
aglatimagene besadenovec
Sensitive
:
C3
BioSpace - 1 week - (New C3)
IDO1 overexpression
Non Small Cell Lung Cancer
IDO1 overexpression
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week (New C3)
PD-L1 inhibitor
Sensitive
:
C3
Clin Cancer Res - 1wk
PD-L1 inhibitor
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week
PD-L1 inhibitor
Sensitive
:
C3
Clin Cancer Res - 1 week - (New C3)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 2 weeks (New B)
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - 2wk
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 2 weeks
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - 2 weeks - (New B)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive: A2 - Guideline
J Neurooncol - 2 weeks (New C3)
EGFR inhibitor
Sensitive
:
A2
J Neurooncol - 2wk
EGFR inhibitor
Sensitive: A2 - Guideline
J Neurooncol - 2 weeks
EGFR inhibitor
Sensitive
:
A2
J Neurooncol - 2 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 2 weeks (New C3)
afatinib
Sensitive
:
A1
Thorac Cancer - 2wk
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 2 weeks
afatinib
Sensitive
:
A1
Thorac Cancer - 2 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 2 weeks (New C3)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Daiichi Sankyo Press Release - 2wk
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 2 weeks
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Daiichi Sankyo Press Release - 2 weeks - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: B - Late Trials
Nat Med - 2 weeks (New C3)
amivantamab-vmjw
Sensitive
:
B
Nat Med - 2wk
amivantamab-vmjw
Sensitive: B - Late Trials
Nat Med - 2 weeks
amivantamab-vmjw
Sensitive
:
B
Nat Med - 2 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
amivantamab-vmjw + lazertinib
Sensitive: B - Late Trials
Nat Med - 2 weeks (New C3)
amivantamab-vmjw + lazertinib
Sensitive
:
B
Nat Med - 2wk
amivantamab-vmjw + lazertinib
Sensitive: B - Late Trials
Nat Med - 2 weeks
amivantamab-vmjw + lazertinib
Sensitive
:
B
Nat Med - 2 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
anlotinib + sintilimab
Sensitive: C2 – Inclusion Criteria
Cancer Med - 2 weeks (New C3)
anlotinib + sintilimab
Sensitive
:
C2
Cancer Med - 2wk
anlotinib + sintilimab
Sensitive: C2 – Inclusion Criteria
Cancer Med - 2 weeks
anlotinib + sintilimab
Sensitive
:
C2
Cancer Med - 2 weeks - (New C3)
EGFR A763_Y764insFQEA
Non Small Cell Lung Cancer
EGFR A763_Y764insFQEA
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks (New C3)
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2wk
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2 weeks - (New C3)
HER-2 M774delinsWLV
Non Small Cell Lung Cancer
HER-2 M774delinsWLV
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks (New C3)
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2wk
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2 weeks - (New C3)
EGFR D770 delinsGY
Non Small Cell Lung Cancer
EGFR D770 delinsGY
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks (New C3)
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2wk
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2 weeks - (New C3)
EGFR exon 18 deletion
Non Small Cell Lung Cancer
EGFR exon 18 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks (New C3)
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2wk
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2 weeks - (New C3)
EGFR L747P
Non Small Cell Lung Cancer
EGFR L747P
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks (New C3)
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2wk
dacomitinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 2 weeks
dacomitinib
Sensitive
:
C3
Transl Cancer Res - 2 weeks - (New C3)
EGFR wild-type + Chr 11p11.11-q12.1
Non Small Cell Lung Cancer
EGFR wild-type + Chr 11p11.11-q12.1
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks (New C3)
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2wk
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR wild-type + Chr 9q21.31-q22.2
Non Small Cell Lung Cancer
EGFR wild-type + Chr 9q21.31-q22.2
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks (New C3)
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2wk
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR wild-type + Chr 7q31.1-q31.31
Non Small Cell Lung Cancer
EGFR wild-type + Chr 7q31.1-q31.31
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks (New C3)
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2wk
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR mutation + Chr 14q31.1-q31.3
Non Small Cell Lung Cancer
EGFR mutation + Chr 14q31.1-q31.3
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks (New C3)
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2wk
EGFR inhibitor
Sensitive: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks
EGFR inhibitor
Sensitive
:
C3
Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR mutation + Chr 1p13.3-p13.1
Non Small Cell Lung Cancer
EGFR mutation + Chr 1p13.3-p13.1
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks (New C3)
EGFR inhibitor
Resistant
:
C3
Pharmgenomics Pers Med - 2wk
EGFR inhibitor
Resistant: C3 – Early Trials
Pharmgenomics Pers Med - 2 weeks
EGFR inhibitor
Resistant
:
C3
Pharmgenomics Pers Med - 2 weeks - (New C3)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib + KPT-9274
Sensitive: D – Preclinical
Mol Cancer Ther - 2 weeks (New D)
sotorasib + KPT-9274
Sensitive
:
D
Mol Cancer Ther - 2wk
sotorasib + KPT-9274
Sensitive: D – Preclinical
Mol Cancer Ther - 2 weeks
sotorasib + KPT-9274
Sensitive
:
D
Mol Cancer Ther - 2 weeks - (New D)
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
gilteritinib
Sensitive: D – Preclinical
Cancer Sci - 2 weeks (New D)
gilteritinib
Sensitive
:
D
Cancer Sci - 2wk
gilteritinib
Sensitive: D – Preclinical
Cancer Sci - 2 weeks
gilteritinib
Sensitive
:
D
Cancer Sci - 2 weeks - (New D)
HLA-A2 positive
Non Small Cell Lung Cancer
HLA-A2 positive
Non Small Cell Lung Cancer
OSE 2101
Sensitive: B - Late Trials
Ann Oncol - 3 weeks (New B)
OSE 2101
Sensitive
:
B
Ann Oncol - 3wk
OSE 2101
Sensitive: B - Late Trials
Ann Oncol - 3 weeks
OSE 2101
Sensitive
:
B
Ann Oncol - 3 weeks - (New B)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive: A1 - Approval
Nihon Yakurigaku Zasshi - 3 weeks (New C3)
sotorasib
Sensitive
:
A1
Nihon Yakurigaku Zasshi - 3wk
sotorasib
Sensitive: A1 - Approval
Nihon Yakurigaku Zasshi - 3 weeks
sotorasib
Sensitive
:
A1
Nihon Yakurigaku Zasshi - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
JAMA Oncol - 3 weeks (New C3)
durvalumab
Sensitive
:
A1
JAMA Oncol - 3wk
durvalumab
Sensitive: A1 - Approval
JAMA Oncol - 3 weeks
durvalumab
Sensitive
:
A1
JAMA Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: B - Late Trials
J&J Press Release - 3 weeks (New B)
amivantamab-vmjw
Sensitive
:
B
J&J Press Release - 3wk
amivantamab-vmjw
Sensitive: B - Late Trials
J&J Press Release - 3 weeks
amivantamab-vmjw
Sensitive
:
B
J&J Press Release - 3 weeks - (New B)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
amivantamab-vmjw + lazertinib
Sensitive: B - Late Trials
J&J Press Release - 3 weeks (New B)
amivantamab-vmjw + lazertinib
Sensitive
:
B
J&J Press Release - 3wk
amivantamab-vmjw + lazertinib
Sensitive: B - Late Trials
J&J Press Release - 3 weeks
amivantamab-vmjw + lazertinib
Sensitive
:
B
J&J Press Release - 3 weeks - (New B)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
lazertinib
Sensitive: B - Late Trials
J Thorac Oncol - 3 weeks (New B)
lazertinib
Sensitive
:
B
J Thorac Oncol - 3wk
lazertinib
Sensitive: B - Late Trials
J Thorac Oncol - 3 weeks
lazertinib
Sensitive
:
B
J Thorac Oncol - 3 weeks - (New B)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
lazertinib
Sensitive: B - Late Trials
J Thorac Oncol - 3 weeks (New B)
lazertinib
Sensitive
:
B
J Thorac Oncol - 3wk
lazertinib
Sensitive: B - Late Trials
J Thorac Oncol - 3 weeks
lazertinib
Sensitive
:
B
J Thorac Oncol - 3 weeks - (New B)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks (New C3)
U3-1402
Sensitive
:
C2
J Clin Oncol - 3wk
U3-1402
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks
U3-1402
Sensitive
:
C2
J Clin Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks (New C3)
U3-1402
Sensitive
:
C2
J Clin Oncol - 3wk
U3-1402
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 3 weeks
U3-1402
Sensitive
:
C2
J Clin Oncol - 3 weeks - (New C3)
EGFR wild-type
Non Small Cell Lung Cancer
EGFR wild-type
Non Small Cell Lung Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
Int J Gen Med - 3 weeks (New C3)
anlotinib
Sensitive
:
C2
Int J Gen Med - 3wk
anlotinib
Sensitive: C2 – Inclusion Criteria
Int J Gen Med - 3 weeks
anlotinib
Sensitive
:
C2
Int J Gen Med - 3 weeks - (New C3)
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
EGFR inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks (New C3)
EGFR inhibitor
Sensitive
:
C3
BMC Cancer - 3wk
EGFR inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
EGFR inhibitor
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
TFRC overexpression + PD-L1 underexpression
Non Small Cell Lung Cancer
TFRC overexpression + PD-L1 underexpression
Non Small Cell Lung Cancer
nivolumab
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks (New C3)
nivolumab
Sensitive
:
C3
Cancers (Basel) - 3wk
nivolumab
Sensitive: C3 – Early Trials
Cancers (Basel) - 3 weeks
nivolumab
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
tepotinib
Sensitive: A1 - Approval
tepotinib
Sensitive
:
A1
tepotinib
Sensitive: A1 - Approval
tepotinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
lazertinib
Sensitive: A1 - Approval
lazertinib
Sensitive
:
A1
lazertinib
Sensitive: A1 - Approval
lazertinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
capmatinib
Sensitive: A1 - Approval
capmatinib
Sensitive
:
A1
capmatinib
Sensitive: A1 - Approval
capmatinib
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
cemiplimab-rwlc
Sensitive: A1 - Approval
cemiplimab-rwlc
Sensitive
:
A1
cemiplimab-rwlc
Sensitive: A1 - Approval
cemiplimab-rwlc
Sensitive
:
A1
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login